

1 **Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized**
2 **trial (the Cobovax study)**

3
4 Nancy H. L. Leung^{*1,2}, Samuel M. S. Cheng^{*1}, Carolyn A. Cohen^{*3}, Mario Martín-Sánchez¹,
5 Niki Y. M. Au¹, Leo L. H. Luk¹, Leo C. H. Tsang¹, Kelvin K. H. Kwan¹, Sara Chaothai¹, Lison
6 W. C. Fung¹, Alan W. L. Cheung³, Karl C. K. Chan¹, John K. C. Li¹, Yvonne Y. Ng¹,
7 Prathanporn Kaewpreedee³, Janice Z. Jia³, Dennis K. M. Ip¹, Leo L. M. Poon^{1,3,4}, Gabriel M.
8 Leung^{†1,2}, J. S. Malik Peiris^{†1,3,4}, Sophie A. Valkenburg^{‡3,5}, Benjamin J. Cowling^{†1,2}

9
10 *Joint first authors with equal contribution

11 †Joint senior authors with equal contribution

12 #Corresponding authors

13
14 **Affiliations:**

15 1. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of
16 Public Health, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong
17 Special Administrative Region, China.

18 2. Laboratory of Data Discovery for Health; Hong Kong Science and Technology Park, New
19 Territories, Hong Kong Special Administrative Region, China.

20 3. HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The
21 University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.

22 4. Centre for Immunology and Infection; Hong Kong Science and Technology Park, New
23 Territories, Hong Kong Special Administrative Region, China.

24 5. Department of Microbiology and Immunology, Peter Doherty Institute of Infection and
25 Immunity, The University of Melbourne, Melbourne, Victoria, Australia.

26

27 Clinicaltrials.gov registration: NCT05057169

28

29 Running head: Crossover trial of CoronaVac and BNT162b2

30 Word count (abstract): 301

31 Word count (main text): 4,500

32

33 **Corresponding authors:**

34 Benjamin Cowling, WHO Collaborating Centre for Infectious Disease Epidemiology and
35 Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong;
36 Hong Kong Special Administrative Region, China. bcowling@hku.hk

37

38 Nancy Leung, WHO Collaborating Centre for Infectious Disease Epidemiology and Control,
39 School of Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong
40 Special Administrative Region, China. leungnan@hku.hk

41

42

43

44 **ABSTRACT**

45 **Background:** There are few trials comparing homologous and heterologous third doses of
46 COVID-19 vaccination with inactivated vaccines and mRNA vaccines.

47 **Methods:** We conducted an open-label randomized trial in adults ≥ 18 years of age who
48 received two doses of inactivated vaccine (CoronaVac) or mRNA vaccine (BNT162b2) ≥ 6
49 months earlier, randomised in 1:1 ratio to receive a third dose of either vaccine. We compared
50 the reactogenicity, immunogenicity and cell-mediated immune responses, and assessed vaccine
51 efficacy against infections during follow-up.

52 **Results:** We enrolled 219 adults who previously received two doses of CoronaVac and
53 randomised to CoronaVac ("CC-C", n=101) or BNT162b2 ("CC-B", n=118) third dose; and 232
54 adults who previously received BNT162b2 and randomised to CoronaVac ("BB-C", n=118) or
55 BNT162b2 ("BB-B", n=114). There were more frequent reports of mild reactions in recipients of
56 third-dose BNT162b2, which generally subsided within 7 days. Third doses significantly
57 increased neutralising PRNT₅₀ antibody titers against ancestral virus and Omicron BA.1 variant
58 in all four study arms, and against Omicron BA.2 in all arms except CC-C, with statistically
59 significant improvements for recipients of a third dose of BNT162b2 over CoronaVac
60 irrespective of prior vaccine type. Boosting of CD4⁺ T cells only occurred in CoronaVac-primed
61 arms, but we did not identify overall differences between vaccine groups in CD4⁺ and CD8⁺ T
62 cell responses. When Omicron BA.2 was circulating, we identified 58 infections with cumulative
63 incidence of 15.3% and 15.4% in the CC-C and CC-B (p=0.93), and 16.7% and 14.0% in the
64 BB-C and BB-B arms, respectively (p=0.56).

65 **Conclusions:** Similar levels of incidence of infection in each arm suggest all third dose
66 combinations may provide similar degrees of protection against prevalent Omicron BA.2

67 infection, despite very weak antibody responses to BA.2 in the recipients of a CoronaVac third
68 dose. Further research is warranted to identify appropriate correlates of protection for inactivated
69 COVID-19 vaccines.

70

71 INTRODUCTION

72 The accrual of population immunity to COVID-19 may ultimately allow communities to return
73 to normal, or at least to a “new-normal”. Immunity can be acquired through surviving infections
74 or, preferably, by vaccination. An unprecedented global effort has led to the rapid development
75 and deployment of COVID-19 vaccines.¹ Vaccines against COVID-19 have generally been
76 developed initially as either a single dose, or two doses of the same vaccine technology platform
77 i.e. a homologous two-dose regimen.¹ The emergence of variants of concern (VOCs)² and
78 observed decrease in vaccine-induced immune responses within a few months after
79 vaccination^{3,4} have led to the implementations of third dose (“booster”) vaccination programs.⁵
80 While some booster campaigns have encouraged individuals to receive a homologous third dose,
81 a third/booster dose with a different vaccine platform, i.e., heterologous vaccination, could be
82 more feasible in some locations.⁶⁻⁸ There is also a possibility that combining vaccine doses using
83 different vaccine platforms by heterologous prime-boost strategies might enhance the immune
84 response.⁹ Heterologous vaccination has been investigated by a number of clinical trials with
85 mixed results depending on the initial platform and sequence of vaccination.^{7,10,11} Conversely,
86 considerations over adverse events may prompt individuals to prefer one vaccine platform over
87 the other.⁸

88
89 In Hong Kong, a subtropical city in southern China, the COVID-19 vaccination programme
90 started in February 2021. The programme initially offered each adult in Hong Kong a choice of
91 two doses of the inactivated whole-virion vaccine CoronaVac (Sinovac) 28 days apart, or two
92 doses of mRNA vaccine BNT162b2 (BioNTech/Fosun Pharma, marketed by Pfizer outside
93 China) 21 days apart, with broad eligibility criteria and availability. Subsequently, healthy adults

94 have been recommended to receive a third dose of either vaccine (i.e., allowing cross-over) as
95 soon as 90 days after the second dose.⁸

96
97 Safety, immunogenicity and efficacy are the main aspects evaluated before vaccines are licensed.
98 There are few trials¹² comparing the potential advantages of homologous or heterologous third
99 doses in individuals who have previously received two doses of an inactivated vaccine or two
100 doses of an mRNA vaccine. Here, we conducted a randomized trial to compare the
101 immunogenicity and reactogenicity to BNT162b2 or CoronaVac in individuals that had
102 previously received two doses of those vaccines. In addition, in early 2022 during the biggest
103 local (fifth) wave the antigenically distinct Omicron BA.2 variant was the major circulating
104 strain,¹³ which provided us an opportunity to evaluate the comparative efficacy of these different
105 vaccine combinations against infection.

106

107 **METHODS**

108 *Trial design and participants*

109 This study is an open-label randomized trial conducted in Hong Kong to measure the vaccine
110 (humoral) immunogenicity and reactogenicity of third doses with an mRNA vaccine
111 (BNT162b2) or an inactivated vaccine (CoronaVac) in adults who have previously received two
112 doses of either vaccine. BNT162b2 is a nucleoside-modified mRNA encoding the trimerized
113 SARS-CoV-2 spike glycoprotein formulated in lipid nanoparticles, and each 0.3mL dose
114 contains 30µg of mRNA. CoronaVac is a Vero cell-based, aluminium hydroxide-adjuvanted, β-
115 propiolactone-inactivated vaccine, and each 0.5 ml dose includes 600SU of inactivated SARS-
116 CoV-2 virus.

117
118 Individuals were eligible for this study if they were Hong Kong residents, ≥ 18 years of age at
119 enrolment and had previously received a homologous two-dose primary series of either
120 BNT162b2 or CoronaVac, with the second dose received at least 6 months (180 days) earlier.
121 Exclusion criteria included: a history of confirmed SARS-CoV-2 infection, a delay of ≥ 43 days
122 between the first two vaccine doses, contraindication for COVID-19 vaccination such as severe
123 allergies, use of medication that could impair the immune system in the last 6 months (except
124 topical steroids or short-term oral steroids), use of immunoglobulins and/or any blood products
125 within 90 days prior to enrolment, and pregnant or nursing, or planning to become pregnant. The
126 study protocol (Clinicaltrials.gov NCT05057169) was approved by the Institutional Review
127 Board of the University of Hong Kong (ref: UW 21-492).

128

129 ***Randomization and masking***

130 The random allocation process was concealed from both participants and the field investigation
131 team, by way of pre-assignment based on a computer-generated sequence of random numbers
132 administered by clicking a randomization button in the online data collection tool REDCap. We
133 used a block randomization structure with block sizes of 2, 4 and 6. The sequence of random
134 numbers was generated prior to the start of the study by a statistician using the computer
135 software package R. For logistical reasons individuals were randomized at the time vaccination
136 appointments were made, and there were dropouts after randomization and before vaccination.
137 However, both the participants and field investigation team were not aware of the intervention
138 until after vaccination, as the vaccination was done by separate unblinded nurses at the
139 community vaccination centres. After vaccination, participants were provided with vaccination

140 cards as required by the local government indicating which vaccine they had received, i.e.
141 participants and field investigation team were also unblinded from this time onwards. The staff
142 conducting laboratory tests were blinded to the third dose allocation.

143

144 *Procedures*

145 Participants were enrolled from the general community (see **Supplementary Information** for
146 additional information on enrolment and follow-up). We collected 20ml blood samples
147 immediately prior to vaccination (Day 0) and scheduled follow-up blood draws at 28, 182 days
148 and 365 days after vaccination. In a voluntary subset of approximately 35% of participants we
149 collected additional 10ml whole blood samples at day 0, 7 and 28 for analysis of cell-mediated
150 immune responses (CMI). At each encounter for a blood draw we offered a HKD100 (USD13)
151 incentive in the form of a supermarket gift voucher. After vaccination, participants were
152 provided with vaccination cards and tympanic thermometers, observed for 15-30 minutes for
153 immediate events, and then provided with an e-diary and requested to record daily on possible
154 (delayed) adverse events or symptoms for 7 days as well as any medical encounters. From March
155 2022, all participants were invited to participate in active surveillance to identify COVID-19 and
156 influenza virus infection using rapid antigen tests (RAT) at home every four days. We also
157 ascertained whether any participants had an infection identified by RAT or PCR after enrolment
158 but prior to the start of active surveillance. The active surveillance is continuing with information
159 collected up to May 31 included in the present analyses.

160

161 ***Outcomes***

162 The primary outcome measure is the immunogenicity at 28 days after the third dose of either
163 BNT162b2 or CoronaVac, measured as geometric mean titer (GMT) of SARS-CoV-2 serum
164 neutralising antibodies using plaque reduction neutralization test (PRNT₅₀). The secondary
165 outcome measures included i) the geometric mean fold rise (MFR) of SARS-CoV-2 serum
166 neutralising antibody titers from baseline (Day 0) to Day 28, ii) magnitude and phenotype of
167 vaccine-specific IFN γ ⁺CD4⁺ and IFN γ ⁺CD8⁺ T-cell responses at Day 7 and 28, iii) the incidence
168 of solicited local and systemic adverse events, and iv) COVID-19 infections after receiving the
169 third vaccine dose.

170

171 ***Sample size justification***

172 For the primary outcome of vaccine immunogenicity, i.e. the GMT of SARS-CoV-2 serum
173 neutralising antibodies against the vaccine strain (ancestral virus) at 28 days after vaccination, a
174 sample size of 100 individuals in each study arm was chosen. Based on our preliminary data,
175 assuming $\log_{10}(\text{GMT}(\text{PRNT}_{50} \text{ at Day 0})) = \log_{10}(27) = 1.4$ with a standard deviation of 0.9, a
176 sample size of 80 individuals per group would provide 80% power to detect a difference in \log_{10}
177 GMT of 0.4 or greater at the 5% significance level. The same calculation applies in each stratum.
178 We aimed for at least 100 individuals in each study arm to allow for the possibility of withdrawal
179 from the study prior to the day 28 assessment.

180

181 ***Laboratory analysis***

182 Blood samples were delivered to our study laboratory at the University of Hong Kong as soon as
183 possible, with the optimal delivery time within 24h. Clotted blood samples were stored in a

184 refrigerated container at 2-8°C immediately after collection and while in transit to the central
185 laboratory. Sera were extracted from the clotted blood samples within 48 hours after collection,
186 divided into 2-4 aliquots, and stored at -80°C until subsequent serologic testing. Heparinized
187 blood samples were kept at room temperature upon collection and while in transit and processed
188 within 24 hours of collection. Peripheral blood mononuclear cells (PBMCs) were isolated from
189 the heparinized (whole) blood using Ficoll-Paque and leucosep tubes, divided into 2 aliquots,
190 and cryopreserved in liquid nitrogen until further analysis for cell-mediated immune responses.

191
192 Details of serologic testing, including our in-house enzyme-linked immunosorbent assay
193 (ELISA) for the receptor binding domain (RBD) of the spike protein, a surrogate virus
194 neutralisation test (sVNT) (GenScript) and a plaque reduction neutralisation test (PRNT), have
195 been described in our earlier study on the immunogenicity of third-dose BNT162b2 after two
196 doses of CoronaVac⁸. We aimed to test sera collected on Day 0 and 28 with ELISA against
197 ancestral virus and sVNT against both ancestral virus and Omicron variant in all participants,
198 and with PRNT against both ancestral virus and Omicron variant in a randomly selected subset
199 of 20 participants in each study arm. We have demonstrated a good correlation ($r=0.77$) between
200 PRNT₅₀ and sVNT neutralization percentage for ancestral virus in our earlier studies¹⁴. The
201 ELISA has a dynamic range of between 0 to 5, although it was not designed as a quantitative
202 assay. For ELISA a single 1:100 serum dilution and for sVNT a single 1:10 serum dilution was
203 tested respectively. For PRNT, a serial two-fold serum dilutions from 1:10 to 1:320 were tested
204 initially, and in participants with an initial PRNT₅₀ titer of ≥ 320 , additional PRNT using a serial
205 two-fold serum dilutions from 1:40 to 1:1280 were performed. PRNT assays were carried out
206 using ancestral SARS-CoV-2 BetaCoV/Hong Kong/VM20001061/2020 (GISAID

207 EPI_ISL_412028) isolated in Vero-E6 cells (ATCC CRL-1586), the Pango lineage B.1.1.529
208 Omicron BA.1 subvariant designated hCoV-19/Hong Kong/VM21044713_WHP5047-S5/2021
209 (GISAID EPI_ISL_6716902) and BA.2 subvariant hCoV-19/Hong
210 Kong/VM22000135_HKUVOC0588P2/2022 (GISAID EPI_ISL_9570707) isolated in Vero-E6
211 TMRSS2 cells (Vero E6 cells overexpressing TMPRSS2, kindly provided by Dr S Matsuyama
212 and colleagues),¹⁵ and the passage level 3 virus aliquots were used. Cells were maintained in
213 DMEM medium supplemented with 10% FBS and 100 U/ml penicillin–streptomycin (all from
214 ThermoFisher Scientific, Waltham, MA, USA). The PRNT₅₀, PRNT₈₀ and PRNT₉₀ titers were
215 the highest serum dilutions neutralising $\geq 50\%$, $\geq 80\%$ and $\geq 90\%$ of input plaques, respectively.
216 The WHO control serum provided by the National Institute for Biological Standards and Control
217 20/136 gave PRNT₅₀ titers of 320 and 320 against the ancestral virus and 20 and 40 against the
218 Omicron variant in two titrations.

219
220 The cell-mediated immune responses to the third dose COVID-19 vaccination, proxy by the
221 cytokine production of IFN γ (in both CD4⁺ and CD8⁺ T cells) or IL4 (in CD4⁺ T cells only) of T
222 cells, were assessed in a randomly-selected subset of 20 participants in each study arm by
223 intracellular cytokine staining (ICS). All testing was done in two experiments with each
224 experiment including 10 participants randomly selected from each study arm, and time point
225 samples collected from the same participant tested in parallel in the same experiment. Samples
226 with a positive value after subtracting the respective value of the DMSO control were classified
227 as having a positive response (“responder”) (value of DMSO control for CD4⁺ IFN γ ⁺ T cells:
228 0.001%; CD8⁺ IFN γ ⁺ T cells: 0.00017%; CD4⁺ IL4⁺ T cells: 0.000039%). Furthermore, CD4⁺
229 and CD8⁺ T cell memory phenotypes (CD45RA/CD27) and cytokine polyfunctional quality

230 (TNF α /IL2) were assessed by gating on IFN γ ⁺ cells for samples which were classified as CD4⁺
231 IFN γ ⁺ T cell or CD8⁺ IFN γ ⁺ T cell responders¹⁶. Cryopreserved PBMCs collected on Day 0, 7
232 and 28 were thawed and re-stimulated with an overlapping peptide pool representing the SARS-
233 CoV-2 structural proteins (spike, nucleocapsid, envelope and membrane) (300nM) or DMSO
234 (1% in RPMI) in two independent experiments. Cells were stimulated for a total of 28 hours at
235 37°C. Golgi Plug (BD) containing Brefeldin A (1% in PBS), and Golgi Stop (BD) containing
236 Monensin (0.67% in PBS) was added at 24 hours during stimulation for further 4-hour
237 incubation. The amino acid sequence of the peptide pools was based on β CoV/Hong
238 Kong/VM20001061/2020 strain (GISAID ID: EPI_ISL_412028). Cells were stained with
239 Zombie-NIR (all antibodies from Biolegend and clone used) followed by anti-human CD3-
240 PE/Dazzle 594 (UCHT1), CD4-BV605 (OKT4), CD8-AlexaFluor700 (SK1), CCR7-
241 PerCP/Cy5.5 (G043H7), PD-1-BV421 (NAT105), CD45RA-APC (HI100), and a dump channel
242 containing CD19-BV510 (HIB19), CD56-BV510 (5.1H11) and CD14-BV510 (M5E2).
243 Following cell permeabilization, intracellular staining with anti-IFN γ -FITC (4S.B3), IL4-PE
244 (MP4-25D2) and TNF α -BV711 (MAb11), IL2-PECy7 (MQ1-17H12), was carried out before
245 acquisition of samples. Stained cells were acquired via flow cytometry (AttuneNxT) and
246 analysed by FlowJo v10. All samples met the cell viability cut-off of at least 30% and thus have
247 been included in the analyses.

248

249 ***Statistical analysis***

250 We included all available data on participants who received a third dose of vaccination in our
251 trial. For post-vaccination reactions, solicited local and systemic events or symptoms were
252 presented as frequency (%) among participants who reported health status for ≥ 7 days in the

253 week following receipt of the third dose. We compared the proportions of the participants with
254 adverse events between the two study arms in individuals who had a prior recipient of two-dose
255 BNT162b2, or who had a prior recipient of two doses of CoronaVac, using the Chi-squared test
256 or Fisher's exact test. Severity score as a proxy of interference to usual activities was calculated
257 by assigning 0-reactions absent, 1-mild, 2-moderate and 3-severe and taking the average over the
258 week after vaccination, and compared between groups using Student's t-tests.

259
260 For antibody responses, for sVNT measured negative neutralization percentages were
261 transformed to zero. PRNT titers were taken as the reciprocal of the serum dilution and were
262 interval-censored, e.g. a sample that was able to neutralise virus at a 1:20 dilution but not at a
263 1:40 dilution was reported as 20 to indicate that the titer was ≥ 20 and < 40 . We estimated the
264 arithmetic mean of SARS-CoV-2 surrogate virus neutralization percentages and concentrations
265 of SARS-CoV-2 Spike RBD IgG (proxy by OD₄₅₀) on Day 28. For PRNT titers, we imputed
266 titers < 10 with the value 5 and titers ≥ 1280 with the value 2560, and then transformed to log₂
267 scale for the estimation of GMT and MFR, and significant testing. We compared antibody levels
268 between Day 0 and Day 28 using Wilcoxon signed rank tests. We compared antibody levels at
269 Day 28 between study arms using Mann-Whitney U tests. For cell-mediated response, we
270 transformed CD4⁺ IFN γ ⁺ T cell, CD8⁺ IFN γ ⁺ T cell and CD4⁺ IL4⁺ T cell responses to log₁₀
271 scale for the estimation of geometric means and fold-rises and significance testing. CD4⁺ and
272 CD8⁺ T cell memory phenotypes and cytokine polyfunctional quality were assumed zeros for
273 CD4⁺/CD8⁺ IFN γ ⁺ T cell non-responders. We compared T cell responses between Day 0 and
274 Day 7, and between Day 0 and Day 28, using Wilcoxon signed rank tests. We compared T cell
275 responses at Day 7, and at Day 28, between study arms using Mann-Whitney U tests.

276

277 We compared the cumulative incidence of infections in each study arm using Kaplan-Meier
278 curves and compared the incidence of infections using proportional hazards model. The
279 proportional hazards model was specified on a calendar time axis with follow up starting from
280 the start of Hong Kong's fifth wave on 1 January 2022 or on the date of third dose if later, and
281 ending at the earliest of the time of infection, the time of receiving a fourth dose, the time of
282 withdrawing from the study, or the censoring date on 31 May 2022. If a participant reported
283 more than one instance of positive result by RAT or PCR, the earliest date of identification was
284 considered the time of infection. All statistical analyses were conducted using R version 4.2.1 (R
285 Foundation for Statistical Computing, Vienna, Austria).

286

287 **RESULTS**

288 From 12 November 2021 through 27 January 2022, we screened 994 individuals and 818 (82%)
289 passed the initial eligibility assessment (**Figure 1, Figure S1**). We randomized 364 individuals
290 to the CC-C (178) and CC-B (186) arms, and 406 individuals to the BB-C (202) and BB-B (204)
291 arms. After final confirmation of eligibility, we collected baseline (Day 0) blood samples from
292 451 participants and then administered third doses, including 101 (57%) CC-C participants, 118
293 (63%) CC-B participants, 118 (58%) BB-C participants, and 114 (56%) BB-B participants.
294 Participant characteristics were generally comparable between the CC-C and CC-B arms, and
295 between the BB-C and BB-B arms (**Table 1**). Participants in the CC-C arm (median aged 58
296 years, IQR 50-64) were slightly older than those in CC-B (52 years, 43-58) ($p = 0.01$). For all
297 451 vaccinated participants, most reported receiving the second dose 6-8 months earlier (**Table**

298 1). A subset of 156 (35%) participants agreed to provide PBMCs samples on Day 0, 7 and Day
299 28 to evaluate cell-mediated immune responses (“CMI group”).

300
301 We collected information on post-vaccination reactions in 424 (94%) participants, including 193
302 (64%) who reported ever feeling unwell after vaccination, with significantly more frequent
303 reactions in recipients of a third dose of BNT162b2 that mostly subsided within 7 days (**Figure**
304 **2, Table S3**). Fever $\geq 38.0^{\circ}\text{C}$ was reported by about 10% of participants in both BB-B and CC-B
305 arms, but by none in BB-C and CC-C arms (**Table S3**). Among 440 participants who reported
306 information on medical care and hospitalisation, 10 reported seeking ambulatory care within one
307 month of the third dose, including 4 (1 in CC-C and 3 in CC-B) for discomfort associated with
308 vaccination (**Table S4**). One BB-B participant reported hospitalisation within a month of
309 vaccination for unrelated reasons (**Table S4**).

310
311 Third-dose vaccination significantly increased neutralising antibodies, measured as sVNT
312 inhibition percentage or PRNT₅₀ titers, against the ancestral virus, Omicron BA.1 and BA.2 on
313 Day 28 from baseline in all four study arms regardless of third dose vaccine type (**Figure 3,**
314 **Figure S4, Table S5**). In both assays, antibody responses to a BNT162b2 third dose were
315 substantially and statistically significantly greater than responses to a CoronaVac third dose
316 (**Figure 3, Figure S2A, Figure S4, Table S5**). Similar results were observed when comparing
317 binding antibodies by ELISA (**Figure S3, Table S6**).

318
319 In a subset of 20 participants randomly selected from each study arm (**Table S2**), we found that
320 vaccination significantly increased the number of IFN γ ⁺ CD4⁺ T cells (indicative of a Th1

321 response) in both CC-C and CC-B arms on Day 7, which remained significantly elevated from
322 Day 0 on Day 28 (**Figure 4A, Figure S2B**). There was no significant change in IFN γ ⁺ CD4⁺ T
323 cells in both BB-C and BB-B arms on both Day 7 and Day 28 (**Figure 4A, Figure S2B**).
324 Separately, 30-50% participants in all arms had IFN γ ⁺ CD8⁺ T cells (indicative of a CTL
325 response) at baseline, but these were only significantly boosted in CC-B arm on Day 7 and
326 contracted by Day 28 (**Figure 4B, Figure S2B**). Meanwhile, IL4⁺ CD4⁺ T cells (indicative of a
327 Th2 response) were not significantly boosted by third doses in any arm (**Figure S2B, Figure**
328 **S5**). There were no significant differences in the magnitude of CD4⁺ and CD8⁺ T cell responses
329 between third doses of CoronaVac or BNT162b2 (**Table S6, Table S7**). We also evaluated the
330 multi-cytokine production (TNF α and IL-2) and memory phenotype of IFN γ -producing CD4⁺ or
331 CD8⁺ T cells. We observed a bias towards single cytokine responses (IFN γ ⁺) as the majority of
332 the T cell responses, but expansions upon vaccination of double cytokine responses (IFN γ ⁺ with
333 TNF α ⁺ or IL-2⁺) in CC-C and CC-B; and T effector memory responses predominated across all
334 arms and were further expanded in CC-C and CC-B (**Figure 4C and 4D, Table S5**).

335
336 We identified 58 SARS-CoV-2 infections by 31 May 2022, within 4-6 months of receipt of the
337 third dose of vaccination. During this period the Omicron BA.2 variant was locally circulating.
338 The number of infections identified by arm was 13/85 (15.3%) in CC-C, 16/104 (15.4%) in CC-
339 B, 16/96 (16.7%) in BB-C and 13/93 (14.0%) in BB-B arms, with no statistically significant
340 difference detected between the CC-C and CC-B arms ($p = 0.93$) nor between the BB-C and BB-
341 B arms ($p = 0.56$) (**Figure 5**). Comparing BB-B and BB-C groups, the hazard ratio for a
342 BNT162b2 third dose compared to a CoronaVac third dose was 0.80 (95% confidence interval:
343 0.39, 1.67) corresponding to a relative vaccine efficacy of 20%, while the hazard ratio for CC-B

344 versus CC-C was 0.97 (95% confidence interval: 0.47, 2.01) corresponding to a relative vaccine
345 efficacy of 3%. Additional information on active surveillance is available in **Supplementary**
346 **Materials**.

347

348 **DISCUSSION**

349 Here, we have conducted a comprehensive assessment of the reactogenicity, antibody response,
350 T cell responses and risk of infection in a randomised trial of homologous and heterologous
351 boosting with BNT162b2 and CoronaVac. Our population had minimal COVID-19 infection
352 history prior to all three doses of vaccination,¹⁷ and absence of known prior COVID-19 infection
353 was one of the inclusion criteria. Furthermore, SARS-CoV-2 infection attack rate in the
354 population of Hong Kong assessed by population based sero-surveillance studies was
355 approximately 1% prior to the fifth wave of infections (unpublished data), thus likelihood of
356 unsuspected infection in this cohort prior to vaccination was low. When evaluating the ability to
357 boost immune response by a third vaccine dose, we showed that regardless of the combinations,
358 a third vaccine dose increased neutralising antibody against all ancestral virus, the Omicron
359 BA.1 and BA.2 variants significantly from baseline (**Figure 3**). The phenotype of the T cell
360 responses was predominantly effector memory and single cytokine producing across all vaccine
361 arms, but CD4⁺ and CD8⁺ T cell responses were only boosted in CC-C and CC-B, and no
362 differences were found between all arms in total magnitude of T cell responses, phenotype or
363 proportion responders (**Figure 4**). Prior influenza research has suggested the differentiation state
364 of T cell responses can impact recall potential at infection and protection from disease.¹⁸ Thus,
365 mRNA vaccine as a booster substantially increased antibody response, and those primed with
366 two-dose inactivated vaccines by receiving mRNA or inactivated vaccine booster will benefit the

367 T cell response, each providing an immunological layer against COVID-19. These findings
368 suggest there is immune benefit of administering either a homologous or heterologous third dose
369 six months after the second dose, especially more prominent in adults who initially received two
370 doses of an inactivated vaccine.

371
372 The humoral and cellular immune results taken together would be indicative of superior efficacy
373 of a third dose of BNT162b2 but that is not what we observed (**Figure 5**). Rates of infection,
374 with Omicron BA.2 predominant in the community, were very similar among study arms
375 (**Figure 5**). This discrepancy may indicate the challenge of using neutralising antibody as a
376 correlate or mediator of protection against infection,^{19,20} at least in comparisons between
377 vaccination strategies of mRNA and inactivated vaccines. Although neutralizing antibody did
378 appear to be a correlate of protection when comparing RNA and adenovirus vectored vaccines
379 and in comparisons between vaccinated and unvaccinated individuals,²¹⁻²³ antibody alone may
380 not explain the protection provided by inactivated vaccines, especially against viruses such as
381 Omicron which have high escape from neutralizing antibody elicited by ancestral virus. T-cell
382 responses may also play a role, as well as potentially non-neutralizing antibodies to internal virus
383 genes such as the nucleocapsid. A discordance between neutralizing antibody titres and vaccine
384 effectiveness against severe disease was also noted by us previously.²⁴ Such differences between
385 vaccine types may not always have been accounted for in immunobridging studies²⁵.

386
387 The CD4⁺ helper T cell response, which has been shown to confer heterologous protection
388 against lung damage from infection by Beta variant in mice,²⁶ was significantly boosted and
389 maintained by both homologous (CC-C) and heterologous (CC-B) third dose after two doses of

390 inactivated vaccine (**Figure 4**). This is consistent with earlier findings,^{27,28} and these studies
391 additionally suggested cross-reactivity against the Omicron variant by a third dose. Conversely,
392 there was no boost of T cell responses neither by a homologous nor heterologous third dose after
393 two doses of BNT162b2 (**Figure 4**), however a high level of responders at baseline was observed
394 in both arms (**Figure 4A and 4B**). The CD8⁺ cytotoxic T cell response, which may have a role in
395 limiting COVID-19 disease severity,^{29,30} was significantly boosted at Day 7 although not
396 maintained to memory (Day 28) by heterologous third-dose BNT162b2 after two doses of
397 CoronaVac (**Figure 4**). While the initial two doses were not randomized and participants did
398 differ in a number of ways (**Table S9**), more participants who previously received two-dose
399 BNT162b2 (80-90% responders) had CD4⁺ T cell responses compared to those who previously
400 received two-dose CoronaVac (60-70% responders), and similar proportions of participants had
401 CD8⁺ T cell response at baseline between all arms (30-50% responders, **Figure 4**). In addition,
402 the baseline CD4⁺ T cell response of participants who received prior two doses of BNT162b2
403 were similar to the levels after third-dose vaccination in participants received prior two doses of
404 CoronaVac (**Figure 4**). These may suggest a ceiling effect on the T cell response among
405 participants who previously received two doses of BNT162b2 and explain the lack of boost in
406 cell-mediated immunity in the BB-C and BB-B arms, which has also been observed
407 elsewhere.^{28,31}

408

409 Our study has several limitations. First, due to logistical challenges, we were only able to
410 randomise at the time vaccination appointment was made but not at vaccination, and nearly half
411 of randomized individuals dropped out before vaccination. However, the rates of dropout were
412 similar across study arms, and we have taken great care in the randomisation and allocation

413 concealment so that individuals dropping out were not aware of their allocated vaccine type.
414 Comparisons between study arms did not identify significant differences in most baseline
415 characteristics measured, except vaccinated participants in CC-B were on average 6 years
416 younger than those in CC-C, and vaccinated participants in BB-B were over twice more likely to
417 have hypertension than those in BB-C (**Table 1**). We also did not observe any significant
418 differences in all antibody and cell-mediated response measured at baseline (**Table S6**). Second,
419 in our study we did not include an unvaccinated control group, nor a two-dose comparison
420 group, to evaluate the additional benefits of third dose over existing two doses. Third, we have
421 only studied neutralising antibodies and T cell response, while other branches of immunity such
422 as non-neutralising antibodies^{32,33} may also contribute to protection and may explain the
423 discrepancy in our immunologic and efficacy data. Finally, our study population consists of
424 adults whom first immune priming was from either mRNA or inactivated vaccination, which is
425 different to many parts of the world where the first immune priming was from natural infection.
426 This might lead to differences in subsequent immune response,³⁴ vaccine effectiveness³⁵ and
427 duration of protection,³⁶ and our study findings should be interpreted with these considerations.
428
429 In conclusion, our results suggest there is immune benefit in both administering a homologous or
430 heterologous third dose 6 months after two doses of inactivated or mRNA vaccination, with
431 similar levels of protection against infection provided by all four combinations. Mass vaccination
432 programmes that offer both inactivated and mRNA vaccines, with explanation on their potential
433 advantages and disadvantages, will help individuals in deciding their preferred option, allow
434 flexibility in vaccine deployment, and encourage vaccine uptake.³⁷ Our finding that neutralizing
435 antibody may not be the dominant correlate of protection for inactivated vaccines, especially

436 against SARS-CoV-2 variants such as Omicron that have significant capacity to evade
437 neutralizing antibody, needs to be considered in the development of “variant proof” COVID-19
438 vaccines or vaccines broadly protective against sarbecoviruses currently in development.³⁸

439

440

441 **REFERENCES**

- 442 1. Bok K, Sitar S, Graham BS, Mascola JR. Accelerated COVID-19 vaccine development:
443 milestones, lessons, and prospects. *Immunity* 2021;54:1636-51.
- 444 2. Sheikh A, McMenamin J, Taylor B, Robertson C, Public Health S, the EIIC. SARS-CoV-
445 2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.
446 *Lancet* 2021;397:2461-2.
- 447 3. Cowling BJ, Wong IOL, Shiu EYC, et al. Strength and durability of antibody responses
448 to BNT162b2 and CoronaVac. *Vaccine* 2022;40:4312-7.
- 449 4. Shrotri M, Navaratnam AMD, Nguyen V, et al. Spike-antibody waning after second dose
450 of BNT162b2 or ChAdOx1. *Lancet* 2021;398:385-7.
- 451 5. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 Vaccine Booster
452 against Covid-19 in Israel. *N Engl J Med* 2021;385:1393-400.
- 453 6. Stuart ASV, Shaw RH, Liu X, et al. Immunogenicity, safety, and reactogenicity of
454 heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-
455 adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority
456 trial. *Lancet* 2022;399:36-49.
- 457 7. Parker EPK, Desai S, Marti M, et al. Emerging evidence on heterologous COVID-19
458 vaccine schedules—To mix or not to mix? *The Lancet Infectious Diseases* 2022;22:438-40.
- 459 8. Leung NHL, Cheng SMS, Martin-Sanchez M, et al. Immunogenicity of a third dose of
460 BNT162b2 to ancestral SARS-CoV-2 & Omicron variant in adults who received two doses of
461 inactivated vaccine. *Clin Infect Dis* 2022.
- 462 9. Dangi T, Class J, Palacio N, Richner JM, Penaloza MacMaster P. Combining spike- and
463 nucleocapsid-based vaccines improves distal control of SARS-CoV-2. *Cell Rep* 2021;36:109664.

- 464 10. Atmar RL, Lyke KE, Deming ME, et al. Homologous and Heterologous Covid-19
465 Booster Vaccinations. *N Engl J Med* 2022;386:1046-57.
- 466 11. Costa Clemens SA, Weckx L, Clemens R, et al. Heterologous versus homologous
467 COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19
468 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. *Lancet*
469 2022;399:521-9.
- 470 12. Parker EPK, Desai S, Marti M, et al. Emerging evidence on heterologous COVID-19
471 vaccine schedules—To mix or not to mix? *Lancet Infect Dis* 2022;22:438-40.
- 472 13. Mefsin YM, Chen D, Bond HS, et al. Epidemiology of Infections with SARS-CoV-2
473 Omicron BA.2 Variant, Hong Kong, January-March 2022. *Emerg Infect Dis* 2022;28.
- 474 14. Lau EH, Hui DS, Tsang OT, et al. Long-term persistence of SARS-CoV-2 neutralizing
475 antibody responses after infection and estimates of the duration of protection. *EClinicalMedicine*
476 2021;41:101174.
- 477 15. Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by
478 TMPRSS2-expressing cells. *Proc Natl Acad Sci U S A* 2020;117:7001-3.
- 479 16. Mok CKP, Cohen CA, Cheng SMS, et al. Comparison of the immunogenicity of
480 BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong. *Respirology* 2022;27:301-10.
- 481 17. Chen LL, Abdullah SMU, Chan WM, et al. Contribution of low population immunity to
482 the severe Omicron BA.2 outbreak in Hong Kong. *Nat Commun* 2022;13:3618.
- 483 18. Sridhar S, Begom S, Bermingham A, et al. Cellular immune correlates of protection
484 against symptomatic pandemic influenza. *Nat Med* 2013;19:1305-12.
- 485 19. Goldblatt D, Alter G, Crotty S, Plotkin SA. Correlates of protection against SARS-CoV-2
486 infection and COVID-19 disease. *Immunol Rev* 2022.

- 487 20. Lim WW, Leung NHL, Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Distinguishing
488 Causation From Correlation in the Use of Correlates of Protection to Evaluate and Develop
489 Influenza Vaccines. *Am J Epidemiol* 2020;189:185-92.
- 490 21. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly
491 predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med*
492 2021;27:1205-11.
- 493 22. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the
494 mRNA-1273 COVID-19 vaccine efficacy clinical trial. *Science* 2022;375:43-50.
- 495 23. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and
496 asymptomatic SARS-CoV-2 infection. *Nat Med* 2021;27:2032-40.
- 497 24. McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two, and three
498 doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based
499 observational study. *The Lancet Infectious Diseases* 2022.
- 500 25. ICMRA COVID-19 Vaccine development: Future steps Workshop. 2021. (Accessed
501 August 9, 2022, 2022, at <https://www.icmra.info/drupal/en/covid-19/24june2021>.)
- 502 26. Kingstad-Bakke B, Lee W, Chandrasekar SS, et al. Vaccine-induced systemic and
503 mucosal T cell immunity to SARS-CoV-2 viral variants. *Proc Natl Acad Sci U S A*
504 2022;119:e2118312119.
- 505 27. Chen Y, Chen L, Yin S, et al. The Third dose of CoronVac vaccination induces broad and
506 potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
507 *Emerg Microbes Infect* 2022;11:1524-36.
- 508 28. Jung MK, Jeong SD, Noh JY, et al. BNT162b2-induced memory T cells respond to the
509 Omicron variant with preserved polyfunctionality. *Nat Microbiol* 2022;7:909-17.

- 510 29. Kedzierska K, Thomas PG. Count on us: T cells in SARS-CoV-2 infection and
511 vaccination. *Cell Rep Med* 2022;3:100562.
- 512 30. Moss P. The T cell immune response against SARS-CoV-2. *Nat Immunol* 2022;23:186-
513 93.
- 514 31. Romero-Olmedo AJ, Schulz AR, Hochstätter S, et al. Dynamics of humoral and T-cell
515 immunity after three BNT162b2 vaccinations in adults older than 80 years. *The Lancet*
516 *Infectious Diseases* 2022;22:588-9.
- 517 32. Bartsch YC, Tong X, Kang J, et al. Omicron variant Spike-specific antibody binding and
518 Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines. *Sci Transl*
519 *Med* 2022;14:eabn9243.
- 520 33. López-Muñoz AD, Kosik I, Holly J, Yewdell JW. Cell surface SARS-CoV-2
521 nucleocapsid protein modulates innate and adaptive immunity. *Science Advances* 2022;8.
- 522 34. Bates TA, McBride SK, Leier HC, et al. Vaccination before or after SARS-CoV-2
523 infection leads to robust humoral response and antibodies that effectively neutralize variants.
524 *Science Immunology* 2022;7.
- 525 35. Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of Previous Infection and
526 Vaccination on Symptomatic Omicron Infections. *N Engl J Med* 2022;387:21-34.
- 527 36. Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19
528 Vaccination and Previous Infection. *N Engl J Med* 2022;386:1207-20.
- 529 37. Sprengholz P, Eitze S, Korn L, Siegers R, Betsch C. The power of choice: Experimental
530 evidence that freedom to choose a vaccine against COVID-19 improves willingness to be
531 vaccinated. *Eur J Intern Med* 2021;87:106-8.

532 38. Morens DM, Taubenberger JK, Fauci AS. Universal Coronavirus Vaccines — An Urgent
533 Need. N Engl J Med 2022;386:297-9.

534

535

536 **Acknowledgements**

537 We gratefully acknowledge colleagues including Teresa So, Justin Wan and Eileen Yu for
538 technical support in preparing and conducting this study; Anson Ho for setting up the database;
539 Julie Au and Lilly Wang for administrative support; Hetti Cheung, Victoria Wong, Bobo Yeung
540 at HKU Health System; Cindy Man and other colleagues at the HKU Community Vaccination
541 Centres at Gleneagles Hospital; and all the study participants for facilitating the study.

542

543 **Funding**

544 This project was supported by the Health and Medical Research Fund (grant no. COVID19F09),
545 and the Theme-based Research Scheme of the Research Grants Council of the Hong Kong
546 Special Administrative Region, China (grant no. T11-705/21-N). BJC is supported by the
547 National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department
548 of Health and Human Services, under contract no. 75N93021C00015, and a RGC Senior
549 Research Fellow Scheme grant (HKU SRFS2021-7S03) from the Research Grants Council of the
550 Hong Kong Special Administrative Region, China. The funding bodies had no role in the design
551 of the study, the collection, analysis, and interpretation of data, or writing of the manuscript.

552

553 **Author contributions**

554 All authors meet the ICMJE criteria for authorship. Each author's contributions to the paper are
555 listed below according to the CRediT model:

556 Conceptualization: NHLL, GML, BJC.

557 Methodology: NHLL, SMSC, CAC, JSMP, SAV, BJC.

558 Formal analysis: NHLL, CAC, MM-S, SAV, BJC.

559 Investigation: CAC, NYMA, LLHL, LCHT, KKHK, SC, LWCF, AWLC, KCKC, JKCL, YYN,
560 PK, JZJ.

561 Funding acquisition: NHLL, GML, BJC.

562 Project administration: NHLL, SMSC, JSMP, SAV, BJC.

563 Supervision: NHLL, SMSC, DKMI, LLMP, JSMP, SAV, BJC.

564 Writing – original draft: NHLL, CAC, MM-S, JSMP, SAV, BJC.

565 Writing – review & editing: NHLL, SMSC, CAC, MM-S, NYMA, LLHL, LCHT, KKHK, SC,
566 LWCF, AWLC, KCKC, JKCL, YYN, PK, JZJ, DKMI, LLMP, GML, JSMP, SAV, BJC.

567

568 **Data availability**

569 Data to reproduce the results shown here will be posted on github after peer review and
570 publication of our article.


571

572 **Competing interests**

573 BJC consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Moderna, Pfizer, Roche and
574 Sanofi Pasteur. BJC has received research funding from Fosun Pharma. The authors report no
575 other potential conflicts of interest.

576

577



578

579

Figure 1. Flow chart of participant enrolment for this open-label randomised trial of

580

CoronaVac or BNT162b2 provided as a third vaccine dose in adults who previously


581

received two doses of either vaccine. A more detailed flow chart with reasons for exclusion at

582

each stage is provided in Supplementary Figure S1.

583



584

585 **Figure 2. Solicited local and systemic reactions during the 7 days after a randomised third**

586 **dose of CoronaVac or BNT162b2 vaccine in adults who previously received two doses of**

587 **either vaccine.** For solicited systemic reactions only the most frequently reported reactions are


588 shown. The four study arms included participants who previously received two-dose CoronaVac

589 and were randomised to receive a third dose of CoronaVac (“CC-C”) (red, left panel) or

590 BNT162b2 (“CC-B”) (blue, left panel), and participants who previously received two-dose

591 BNT162b2 and were randomised to receive a third dose of CoronaVac (“BB-C”) (red, right

592 panel) or BNT162b2 (“BB-B”) (blue, right panel).



593

594 **Figure 3. Serum neutralising antibodies against (A, D) ancestral SARS-CoV-2 virus, (B, E)**

595 **Omicron BA.1 and (C, F) Omicron BA.2 variants at baseline and 28 days after a**

596 **randomised third dose of CoronaVac or BNT162b2 vaccine in adults who previously**

597 **received two doses of either vaccine, measured by live virus plaque reduction**

598 **neutralization test (PRNT) or surrogate virus neutralization test (sVNT) respectively.**

599 PRNT titers were evaluated with endpoint at 50% inhibition (PRNT₅₀). Data on PRNT was

600 available from a random subset of 20 participants selected from each study arm. The four study

601 arms included participants who previously received two-dose CoronaVac and were randomised


602 to receive a third dose of CoronaVac (“CC-C”) or BNT162b2 (“CC-B”), and participants who

603 previously received two-dose BNT162b2 and were randomised to receive a third dose of

604 CoronaVac (“BB-C”) or BNT162b2 (“BB-B”). The symbol X and the numbers above each panel

605 indicate the mean level. p-values ≤ 0.05 *, ≤ 0.01 **, ≤ 0.001 ***

606



607

608

Figure 4. CD4⁺ (A, C) and CD8⁺ (B, D) T cell responses against structural peptides of

609

ancestral SARS-CoV-2 virus at baseline, and 7 and 28 days after a randomised third dose

610

of CoronaVac or BNT162b2 vaccine in adults who previously received two doses of either

611

vaccine, measured by (A, B) IFN γ production, (C, D) the ability to poly-cytokine

612

production and memory phenotypes. Data was available from a random subset of 20

613

participants selected from each study arm. The four study arms included participants who

614

previously received two-dose CoronaVac and were randomised to receive a third dose of

615

CoronaVac (“CC-C”) or BNT162b2 (“CC-B”), and participants who previously received two-

616

dose BNT162b2 and were randomised to receive a third dose of CoronaVac (“BB-C”) or

617

BNT162b2 (“BB-B”). The dotted lines represent the lower limits of detection based on DMSO

618

controls and participants with values above these thresholds are considered as responders:

619


0.001% for CD4⁺ IFN γ ⁺ T cells and 0.00017% for CD8⁺ IFN γ ⁺ T cells. The numbers above each

620

panel indicate the mean level, while the percentages indicate the proportion of responder. p-

621

values ≤ 0.05 *, ≤ 0.01 **, ≤ 0.001 ***



622

623 **Figure 5. Cumulative incidence of SARS-CoV-2 infection after a randomised third dose of**
624 **CoronaVac or BNT162b2 vaccine, in adults who previously received two doses of (A)**

625 **CoronaVac or (B) BNT162b2, from after third-dose vaccination until 31 May 2022. The**

626 four study arms included participants who previously received two-dose CoronaVac and were

627 randomised to receive a third dose of CoronaVac (“CC-C”) or BNT162b2 (“CC-B”), and

628 participants who previously received two-dose BNT162b2 and were randomised to receive a

629 third dose of CoronaVac (“BB-C”) or BNT162b2 (“BB-B”). SARS-CoV-2 infections were

630 identified by rapid antigen test or PCR.

631

632

633 **Table 1. Characteristics of all vaccinated participants at baseline.** We enrolled adults who
 634 previously received two doses of CoronaVac or BNT162b2, and randomly assigned participants
 635 to receive either vaccine as a third dose, i.e. the four study arms included participants who
 636 previously received two-dose CoronaVac and were randomised to receive a homologous third
 637 dose of CoronaVac (“CC-C”) or a heterologous third dose of BNT162b2 (“CC-B”), and
 638 participants who previously received two-dose BNT162b2 and were randomised to receive a
 639 heterologous third dose of CoronaVac (“BB-C”) or a homologous third dose of BNT162b2
 640 (“BB-B”). Differences with p-values ≤ 0.05 were highlighted in bold.

Characteristic	All enrolled and received third dose vaccination (N = 451)	Received two-dose CoronVac (CC)			Received two-dose BNT162b2 (BB)		
		Randomised to		p- value	Randomised to		p- value
		CoronaVac (CC-C)	BNT162b2 (CC-B)		CoronaVac (BB-C)	BNT162b2 (BB-B)	
		(N = 101)	(N = 118)	(N = 118)	(N = 114)		
n (%)	n (%)	n (%)	n (%)	n (%)			
Female	221 (49)	47 (47)	64 (54)	0.13	51 (43)	59 (52)	0.5
Age (median, IQR)	54 (47-60)	58 (50-64)	52 (43-58)	0.01	56 (47-60)	53 (46-59)	0.55
Age group (years)							
Underweight (BMI < 18.5)	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	
Normal (BMI 18.5 – 22.9)	22 (5)	5 (5)	5 (4)		5 (4)	7 (6)	
Overweight (BMI 23.0 – 24.9)	38 (8)	8 (8)	13 (11)		8 (7)	9 (8)	
Obese (BMI ≥ 25.0)	100 (22)	13 (13)	34 (29)		27 (23)	26 (23)	
Underweight (BMI < 18.5)	173 (38)	36 (36)	45 (38)		47 (40)	45 (39)	

Normal (BMI 18.5 – 22.9)	99 (22)	33 (33)	20 (17)		28 (24)	18 (16)	
Overweight (BMI 23.0 – 24.9)	19 (4)	6 (6)	1 (1)		3 (3)	9 (8)	
Obese (BMI \geq 25.0)	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	
Chinese	443 (98)	100 (99)	116 (98)	0.31	116 (98)	111 (97)	0.79
Obesity (for Asian populations)							
Underweight (BMI < 18.5)	23 (5)	6 (6)	6 (5)	0.97	4 (3)	7 (6)	0.6
Normal (BMI 18.5 – 22.9)	187 (41)	45 (45)	52 (44)		50 (42)	40 (35)	
Overweight (BMI 23.0 – 24.9)	99 (22)	20 (20)	22 (19)		28 (24)	29 (25)	
Obese (BMI \geq 25.0)	142 (31)	30 (30)	38 (32)		36 (31)	38 (33)	
Chronic medical conditions							
Any	104 (23)	21 (21)	21 (18)	>0.99	30 (25)	32 (28)	0.9
Lung disease, including COPD and asthma	3 (1)	2 (2)	0 (0)	0.5	0 (0)	1 (1)	>0.99
Heart disease	5 (1)	2 (2)	1 (1)	>0.99	2 (2)	0 (0)	0.5
Hypertension	45 (10)	9 (9)	10 (8)	>0.99	7 (6)	19 (17)	0.03
Diabetes	13 (3)	6 (6)	2 (2)	0.29	3 (3)	2 (2)	>0.99
Hypercholesterolemia	28 (6)	7 (7)	3 (3)	0.34	9 (8)	9 (8)	>0.99
Kidney disease	1 (0)	0 (0)	0 (0)	>0.99	1 (1)	0 (0)	>0.99
Liver disease	7 (2)	1 (1)	2 (2)	>0.99	2 (2)	2 (2)	>0.99
Cancer	6 (1)	3 (3)	2 (2)	>0.99	0 (0)	1 (1)	>0.99

Days between first and second dose of COVID-19 vaccination (median, IQR)	27 (21-28)	28 (28-29)	28 (28-29)	0.59	21 (21-23)	21 (21-24)	0.63
Days between second and third (study) dose of COVID-19 vaccination (median, IQR)	232 (200-247)	236 (211-245)	236 (214-247)	0.51	226 (195-246)	222 (196-249)	0.98
Smoking							
Ever	20 (4)	8 (8)	7 (6)	>0.99	2 (2)	3 (3)	>0.99
Current	11 (2)	4 (4)	5 (4)	>0.99	1 (1)	1 (1)	>0.99

641

642